Clinical Trial Update: Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL [Phase 3]

View source ↗

Summary

Phase 3 trial results for AMR101 (ethyl esters of eicosapentaenoic acid) in patients with fasting triglycerides 500–2000 mg/dL; study completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• AMR101 (ethyl icosapentate)

Snippet

Sponsor: Amarin Pharma Inc. | Conditions: Hypertriglyceridemia | Phase 3 | Status: COMPLETED | Results posted: 2022-04-25